Introduction In HRS-AKI, terlipressin improves reversal rates in trials (e.g., CONFIRM), but real-world effectiveness and respiratory adverse events remain uncertain. Following CONFIRM, the MHRA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results